Scientists have long known that people living with HIV face a higher risk of heart disease. The statin drug pitavastatin, however, might offer a solution. In a phase 3 clinical trial, individuals with ...
Please provide your email address to receive an email when new articles are posted on . In patients with HIV at low to moderate CVD risk, pitavastatin lowered noncalcified plaque volume and reduced ...
A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...
In patients with HIV infection but without preexisting cardiovascular disease, lipid-lowering treatment results in large and significant reductions in major adverse cardiovascular events, full results ...
According to interim results from the REPRIEVE study, individuals with HIV who took the daily statin experienced a 35% reduced risk of major adverse cardiovascular (CVD) events, compared with those ...
Ms. C*, a 53-year-old African American woman living with HIV for almost a decade, inquired about the recently released recommendations for cardiovascular disease prevention among people with HIV (PWH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results